Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | FLT4 | P35916 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17649302 | 1.00 | EGFR (0.53) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL17647991 | 0.91 | PTGS2 (0.55) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL17647887 | 0.89 | EGFR (0.52) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL29915627 | 0.89 | EGFR (0.52) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL29915847 | 0.88 | PTGS2 (0.50) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL17647695 | 0.88 | PTGS2 (0.50) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL17648419 | 0.87 | FLT1 (0.51) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL29917470 | 0.87 | FLT1 (0.51) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL17648205 | 0.86 | EGFR (0.49) | EGFRPTGS2PTGS1FLT1FLT4 | |
| SCHEMBL29916131 | 0.86 | EGFR (0.49) | EGFRPTGS2PTGS1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3798214-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2022-09-14 | — | — | EP | claimed |